Regeneron: 3 Key Takeaways for Long-Term Investors

On its third quarter of 2026 earnings call, held on Oct. 30, 2026, Regeneron (REGN +13.33%) reported total revenue of $5.1 billion, representing 36% year-over-year growth. The company’s combination of expanding commercial blockbusters and a proprietary genetics discovery engine supports durable cash flow. Three key takeaways from management highlight the primary drivers of long-term value creation.

1. Dupixent Expansion and Alliance Amendments Secure Core Cash Flow

Dupixent, an injectable biologic drug that blocks inflammatory pathways, reached record sales while management extended its development alliance with Sanofi to co-fund next-generation therapies.

DUPIXENT global net sales in the third quarter as reported by Sanofi reached a record $6.5 billion up 35% year over year at constant currency. Which is truly remarkable for a medicine approaching 10 years on the market.
— Dr. Leonard S. Schleifer, Cofounder, Board Cochair, President and Chief Executive Officer

2. EYLEA HD Accelerates Market Transition in Eye Care

Sales of EYLEA HD, a high-dose injectable treatment for retinal eye diseases, expanded rapidly to offset lower demand for the original formulation amid rising competition.

Third quarter EYLEA HD net sales in The U.S. were $699 million up 62% versus prior year. These results demonstrate strong physician unit demand, which grew 20% from the second quarter.
— Marion McCourt, Executive Vice President, Commercial

3. Internal Genetics Engine Delivers Promising Liver Disease Pipeline

Early clinical trials of an siRNA (small interfering RNA) gene-silencing therapy targeting CIDEB for nonalcoholic steatohepatitis, a metabolic liver disease, demonstrated substantial fat reduction.

In the initial data from 40 participants, a single dose was well tolerated and reduced liver fat by approximately 70% on average from baseline in just 12 weeks. Bringing mean liver fat to near or below the upper limit of normal at every dose level tested.
— Dr. George D. Yancopoulos, Cofounder, Board Cochair, President, and Chief Scientific Officer

Looking Ahead

Commercial infrastructure already reaches major medical specialties, positioning new pipeline candidates to launch without heavy commercial building costs. Research spending is set to increase by a mid-teens percentage in 2027 to fund 15 late-stage clinical trials.

In summary, we have strong momentum across our broad and diverse pipeline that we believe that has the potential to change the practice of medicine across many diseases with high unmet need.
— Dr. George D. Yancopoulos, Cofounder, Board Cochair, President, and Chief Scientific Officer

Internal research tools continue generating drug candidates, while capital allocation prioritizes high-return clinical programs alongside share repurchases.

In conclusion, we delivered another outstanding quarter and remain well positioned to invest in our differentiated pipeline delivering important medicines to patients and create durable long term value for shareholders.
— Christopher R. Fenimore, Executive Vice President Finance, and Chief Financial Officer

The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool has a disclosure policy.

Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.